Max Reichert, MD is a physician-scientist and holds the Professorship for Translational Pancreatic Cancer Research. He is one of the Directors of Center for Organoid Systems (COS) at the Technical University of Munich (TUM). As a senior physician, he is part of the leadership of the Clinic and Policlinic of Internal Medicine II (Gastroenterology) and he is heading Pancreatic Cancer Clinic of the Comprehensive Cancer Center Munich TUM. He founded the Center for Translational Pancreatic Cancer Research at Klinikum rechts der Isar including its key infrastructure – the TUM Patient-derived  Organoid Repository. Dr. Reichert’s research focuseson the molecular underpinnings of cellular plasticity driven intra-tumoral heterogeneity in cancer initiation and dissemination as well as resistance to chemotherapy. Developing translational concepts for precision oncology using innovative in vivo and in vitro model systems such as advanced organoid models to address fundamental questions related to both basic as well as translational cancer biology. Ultimately, Dr. Reichert’s aim is to develop novel therapeutic approaches to induce therapeutic vulnerabilities which can be tested in multicenter randomized clinical trials and exploited in clinical care to improve pancreatic cancer patient outcomes.